Compare DBVT & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBVT | CTKB |
|---|---|---|
| Founded | 2002 | 1990 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.0M | 433.8M |
| IPO Year | N/A | 2021 |
| Metric | DBVT | CTKB |
|---|---|---|
| Price | $13.02 | $5.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $15.85 | $5.88 |
| AVG Volume (30 Days) | 118.6K | ★ 1.9M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,502,000.00 | ★ $196,828,000.00 |
| Revenue This Year | $1,743.46 | N/A |
| Revenue Next Year | $1,045.66 | $7.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $2.37 |
| 52 Week High | $18.00 | $7.30 |
| Indicator | DBVT | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 66.53 |
| Support Level | $12.70 | $5.15 |
| Resistance Level | $14.68 | $5.95 |
| Average True Range (ATR) | 0.93 | 0.43 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 21.86 | 66.15 |
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.